RBC maintains Outperform rating on Vertex Pharmaceuticals
RBC Capital maintained an Outperform rating on Vertex Pharmaceuticals.
Story updates
02:26:20 PM UTC
SquawkNews
Vertex Pharmaceuticals Is Maintained at Outperform by RBC Capital
02:26:35 PM UTC
SquawkNews
Vertex Pharmaceuticals Price Target Raised to $576.00/Share From $570.00 by RBC Capital